BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33080701)

  • 21. Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.
    Onozawa H; Saito H; Sunami K; Kubo T; Yamamoto N; Kasajima R; Ohtsu T; Hiroshima Y; Kanamori H; Yokose T; Miyagi Y
    Thorac Cancer; 2020 Dec; 11(12):3599-3604. PubMed ID: 33034420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report.
    Kano Y; Kataoka N; Kunimatsu Y; Tsutsumi R; Sato I; Tanimura M; Nakano T; Tanimura K; Takeda T
    Medicina (Kaunas); 2022 May; 58(6):. PubMed ID: 35743969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
    Yang Z; Yang J; Chen Y; Shao YW; Wang X
    Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.
    Oztan A; Fischer S; Schrock AB; Erlich RL; Lovly CM; Stephens PJ; Ross JS; Miller V; Ali SM; Ou SI; Raez LE
    Lung Cancer; 2017 Sep; 111():84-87. PubMed ID: 28838405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay.
    Menon R; Müller J; Schneider P; Lakis S; Thress K; Wolf J; Heukamp L; Heuckmann JM; Griesinger F
    J Thorac Oncol; 2016 Sep; 11(9):e105-7. PubMed ID: 27086175
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
    Ouyang W; Yu J; Zhou Y; Hu J; Huang Z; Zhang J; Xie C
    BMC Cancer; 2020 Jul; 20(1):699. PubMed ID: 32723319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uterine metastasis of lung adenocarcinoma under molecular target therapy with epidermal growth factor receptor tyrosine kinase inhibitors: A case report and review of the literature.
    Shibata M; Shizu M; Watanabe K; Takeda A
    J Obstet Gynaecol Res; 2018 Feb; 44(2):352-358. PubMed ID: 29094453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.
    Ham JS; Kim S; Kim HK; Byeon S; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Han J; Park W; Ahn MJ
    J Thorac Oncol; 2016 Jan; 11(1):e1-4. PubMed ID: 26762749
    [No Abstract]   [Full Text] [Related]  

  • 30. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung.
    Reichegger H; Jochum W; Förbs D; Hader C; Früh M
    Oncol Res Treat; 2016; 39(7-8):461-3. PubMed ID: 27486808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
    Miyawaki T; Kenmotsu H; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
    BMC Cancer; 2021 Nov; 21(1):1247. PubMed ID: 34798865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer.
    Zhang L; Sun L; Mu XY; Ji YX
    Chin Med Sci J; 2019 Nov; 34(4):292-296. PubMed ID: 33906716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
    Auliac JB; Saboundji K; Andre M; Madelaine J; Quere G; Masson P; Vergnenegre A; Lamy R; Raymond S; Chiappa AM; Hauss PA; Fournel P; Corre R; Chouaid C
    Target Oncol; 2019 Jun; 14(3):307-314. PubMed ID: 31119481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
    Li SH; Hsieh MH; Fang YF
    Medicine (Baltimore); 2015 Oct; 94(41):e1739. PubMed ID: 26469914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.
    Knetki-Wróblewska M; Kowalski DM; Czyżewicz G; Bryl M; Wrona A; Dziadziuszko R; Kieszko R; Milanowski J; Świniuch D; Ramlau R; Krzakowski M
    Adv Respir Med; 2020; 88(3):189-196. PubMed ID: 32706102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report.
    Chuang X; Chen Y; Yu P; Qiu X; Wang J; Qu X; Teng Y; Liu Y; Jin B
    Thorac Cancer; 2018 Nov; 9(11):1513-1518. PubMed ID: 30144282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
    Yan Y; Jiang G; Ma W; Li T; Wang L
    Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Okuno T; Arakawa S; Yoshida T; Ohe Y
    Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
    [No Abstract]   [Full Text] [Related]  

  • 40. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.